AMBS — Amarantus Bioscience Holdings Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.19m
- $39.02m
Annual income statement for Amarantus Bioscience Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2013 December 31st | 2014 December 31st | 2015 December 31st | 2017 December 31st | 2018 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.4 | 22.6 | 26.1 | 3.26 | 3.04 |
| Operating Profit | -12.4 | -22.6 | -26.1 | -3.26 | -3.04 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.1 | -27.3 | -25.2 | -4.63 | -10.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.1 | -27.3 | -25.2 | -4.63 | -10.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.1 | -27.3 | -25.2 | -4.63 | -10.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -15.2 | -28.2 | -37.1 | -4.63 | -10.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.82 | -5.11 | -4.03 | — | — |
| Dividends per Share |